Similar articles

• Infliximab More Effective in Therapy-Naïve Than in Therapy-Refractory Patients.

  Cozijnsen MA, de Ridder L. Cozijnsen MA, et al. J Pediatr Gastroenterol Nutr. 2015 Sep;61(3):e15. doi: 10.1097/MPG.0000000000000884. J Pediatr Gastroenterol Nutr. 2015. PMID: 26111298 No abstract available.
• Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease.

  Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Lee YM, et al. J Pediatr Gastroenterol Nutr. 2015 Jun;60(6):737-43. doi: 10.1097/MPG.0000000000000711. J Pediatr Gastroenterol Nutr. 2015. PMID: 25564801
• Rapid infliximab infusions are generally well-tolerated in children with inflammatory bowel disease.

  Glover C, Phuong L, Hinds R. Glover C, et al. J Paediatr Child Health. 2017 Jan;53(1):94-95. doi: 10.1111/jpc.13384. J Paediatr Child Health. 2017. PMID: 28070959 No abstract available.
• Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort.

  Vitale DS, Greenley RN, Lerner DG, Mavis AM, Werlin SL. Vitale DS, et al. J Pediatr Gastroenterol Nutr. 2015 Oct;61(4):408-10. doi: 10.1097/MPG.0000000000000817. J Pediatr Gastroenterol Nutr. 2015. PMID: 25885878
• Dose escalation of biologics in Crohn's disease: critical review of observational studies.

  Einarson TR, Bereza BG, Ying Lee X, Lelli F. Einarson TR, et al. Curr Med Res Opin. 2017 Aug;33(8):1433-1449. doi: 10.1080/03007995.2017.1335001. Epub 2017 Jun 11. Curr Med Res Opin. 2017. PMID: 28537467 Review.